Compare ASC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | PRTC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.7M | 464.3M |
| IPO Year | 2013 | N/A |
| Metric | ASC | PRTC |
|---|---|---|
| Price | $13.67 | $16.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 852.6K | 4.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.32 | $13.30 |
| 52 Week High | $16.91 | $20.00 |
| Indicator | ASC | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 42.95 |
| Support Level | $10.42 | $16.51 |
| Resistance Level | $16.91 | $18.10 |
| Average True Range (ATR) | 0.62 | 0.53 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 6.58 | 13.87 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.